Phase 2
Gilead released results from a Phase II clinical trial of GS-0976 for NASH.
The drug developed by Nogra always seemed like a longshot, but Celgene management talked it up over the years as it advanced.
Finding a treatment for Sanfilippo Syndrome is a personal matter for the Lysogene team.
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
The good news led Ignyta’s stock to jump about five percent before settling down.
OncBioMune has begun the process to initiate clinical studies of OvcaVax for ovarian cancer.
Strong, durable responses seen against lung tumors and brain metastases across multiple lines of therapy.
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
PRESS RELEASES